142 related articles for article (PubMed ID: 10416611)
1. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors.
Zheng P; Sarma S; Guo Y; Liu Y
Cancer Res; 1999 Jul; 59(14):3461-7. PubMed ID: 10416611
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
3. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
Ramarathinam L; Castle M; Wu Y; Liu Y
J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683
[TBL] [Abstract][Full Text] [Related]
4. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
5. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.
Wolpert EZ; Petersson M; Chambers BJ; Sandberg JK; Kiessling R; Ljunggren HG; Kärre K
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11496-501. PubMed ID: 9326638
[TBL] [Abstract][Full Text] [Related]
6. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
7. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
Schendel DJ; Falk CS; Nössner E; Maget B; Kressenstein S; Urlinger S; Tampé R; Gansbacher B
Gene Ther; 2000 Jun; 7(11):950-9. PubMed ID: 10849555
[TBL] [Abstract][Full Text] [Related]
8. Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
Zhou X; Momburg F; Liu T; Abdel Motal UM; Jondal M; Hämmerling GJ; Ljunggren HG
Eur J Immunol; 1994 Aug; 24(8):1863-8. PubMed ID: 8056044
[TBL] [Abstract][Full Text] [Related]
9. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport.
Cerundolo V; Kelly A; Elliott T; Trowsdale J; Townsend A
Eur J Immunol; 1995 Feb; 25(2):554-62. PubMed ID: 7875220
[TBL] [Abstract][Full Text] [Related]
10. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
[TBL] [Abstract][Full Text] [Related]
11. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Seliger B; Höhne A; Knuth A; Bernhard H; Ehring B; Tampé R; Huber C
Clin Cancer Res; 1996 Aug; 2(8):1427-33. PubMed ID: 9816317
[TBL] [Abstract][Full Text] [Related]
12. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells.
Guilloux Y; Bai XF; Liu X; Zheng P; Liu Y
Cancer Res; 2001 Feb; 61(3):1107-12. PubMed ID: 11221840
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
14. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
15. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
Huang AY; Bruce AT; Pardoll DM; Levitsky HI
J Exp Med; 1996 Mar; 183(3):769-76. PubMed ID: 8642281
[TBL] [Abstract][Full Text] [Related]
16. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
Kim TS; Lee BC; Kim E; Cho D; Cohen EP
Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
[TBL] [Abstract][Full Text] [Related]
18. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells.
Maric M; Zheng P; Sarma S; Guo Y; Liu Y
Cancer Res; 1998 Aug; 58(15):3376-84. PubMed ID: 9699669
[TBL] [Abstract][Full Text] [Related]
19. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
20. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
